Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $29.2M in Stock for its fiscal quarter ending in July of 2024. Data for Peregrine Pharmaceuticals | PPHM - Stock including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $454.7M in Market Capitalization this April of 2024, considering the latest stock price and the number of outstanding shares.Data for Peregrine Pharmaceuticals | PPHM - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $74.16M in Current Liabilities for its fiscal quarter ending in October of 2024. Data for Peregrine Pharmaceuticals | PPHM - Current Liabilities including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported 63.24M in Outstanding Shares in April of 2024. Data for Peregrine Pharmaceuticals | PPHM - Outstanding Shares including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported 1.66K in PE Price to Earnings for its fiscal quarter ending in March of 2023. Data for Peregrine Pharmaceuticals | PPHM - PE Price to Earnings including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $323.48M in Assets for its fiscal quarter ending in October of 2024. Data for Peregrine Pharmaceuticals | PPHM - Assets including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $160.49M in Debt for its fiscal quarter ending in October of 2024. Data for Peregrine Pharmaceuticals | PPHM - Debt including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $96.5M in Current Assets for its fiscal quarter ending in October of 2024. Data for Peregrine Pharmaceuticals | PPHM - Current Assets including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $-5530000 in Net Income for its fiscal quarter ending in July of 2024. Data for Peregrine Pharmaceuticals | PPHM - Net Income including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $50K in Interest Income for its fiscal quarter ending in June of 2022. Data for Peregrine Pharmaceuticals | PPHM - Interest Income including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $9.25M in Trade Creditors for its fiscal quarter ending in October of 2024. Data for Peregrine Pharmaceuticals | PPHM - Trade Creditors including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $-11222000 in EBIT for its fiscal quarter ending in September of 2023. Data for Peregrine Pharmaceuticals | PPHM - Ebit including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $-2460000 in Operating Profit for its fiscal quarter ending in July of 2024. Data for Peregrine Pharmaceuticals | PPHM - Operating Profit including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $42.63M in Operating Expenses for its fiscal quarter ending in July of 2024. Data for Peregrine Pharmaceuticals | PPHM - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $160.59M in Loan Capital for its fiscal quarter ending in July of 2024. Data for Peregrine Pharmaceuticals | PPHM - Loan Capital including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $33.48M in Sales Revenues for its fiscal quarter ending in October of 2024. Data for Peregrine Pharmaceuticals | PPHM - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $-8368000 in EBITDA for its fiscal quarter ending in September of 2023. Data for Peregrine Pharmaceuticals | PPHM - Ebitda including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $30.21M in Trade Debtors for its fiscal quarter ending in October of 2024. Data for Peregrine Pharmaceuticals | PPHM - Trade Debtors including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals reported $35.53M in Cost of Sales for its fiscal quarter ending in October of 2024. Data for Peregrine Pharmaceuticals | PPHM - Cost Of Sales including historical, tables and charts were last updated by Trading Economics this last July in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Peregrine Pharmaceuticals stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.